<DOC>
	<DOC>NCT02766517</DOC>
	<brief_summary>This is a study of participants with a diagnosis of migraine who completed another clinical trial known as I5Q-MC-CGAB (CGAB) (NTC02163993). In CGAB, participants received either LY2951742 or placebo. This study will evaluate how certain biomarkers may be related to the participant's response in CGAB. The study will last about five days.</brief_summary>
	<brief_title>Biomarker Study in Participants With Migraine</brief_title>
	<detailed_description />
	<mesh_term>Migraine Disorders</mesh_term>
	<mesh_term>Capsaicin</mesh_term>
	<criteria>Participants with migraine who have previously participated in study I5QMCCGAB and received one of the selected doses of LY2951742 or placebo Have suitable skin characteristics for the dermal capsaicin challenge Have a history of significant allergies, in particular to ethanol or sensitivity to the fruits of capsicum plants (for example, chili peppers) Have eczema, scleroderma, psoriasis, dermatitis, keloids, tumors, ulcers, burns, flaps, or grafts on their forearm or other abnormality of the skin which may interfere with the study assessments Cannot avoid excess tanning (any exposure to sunlight or a tanning bed which would cause a sunburn reaction) throughout the study and cannot cover forearms for 24 hours prior to each treatment period Have excessive hair growth on the volar surface of the forearm or participants currently using lotions, oils, depilatory preparations, or other topical treatments on a regular basis which cannot be discontinued for the duration of the study; has used any topical treatments within 7 days of the start of the study</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
</DOC>